CN111826417A - N-acetyl-beta-D-glucosaminidase detection kit with good stability, preparation method and application - Google Patents
N-acetyl-beta-D-glucosaminidase detection kit with good stability, preparation method and application Download PDFInfo
- Publication number
- CN111826417A CN111826417A CN202010771208.9A CN202010771208A CN111826417A CN 111826417 A CN111826417 A CN 111826417A CN 202010771208 A CN202010771208 A CN 202010771208A CN 111826417 A CN111826417 A CN 111826417A
- Authority
- CN
- China
- Prior art keywords
- reagent
- acetyl
- beta
- glucosaminidase
- good stability
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
- C12Q1/44—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving esterase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/26—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/902—Oxidoreductases (1.)
- G01N2333/90219—Oxidoreductases (1.) acting on diphenols and related substances as donors (1.10)
- G01N2333/90222—Oxidoreductases (1.) acting on diphenols and related substances as donors (1.10) with oxygen as acceptor (1.10.3) in general
- G01N2333/90225—Oxidoreductases (1.) acting on diphenols and related substances as donors (1.10) with oxygen as acceptor (1.10.3) in general with a definite EC number (1.10.3.-)
- G01N2333/90235—Ascorbate oxidase (1.10.3.3)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/916—Hydrolases (3) acting on ester bonds (3.1), e.g. phosphatases (3.1.3), phospholipases C or phospholipases D (3.1.4)
- G01N2333/918—Carboxylic ester hydrolases (3.1.1)
- G01N2333/92—Triglyceride splitting, e.g. by means of lipase
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/924—Hydrolases (3) acting on glycosyl compounds (3.2)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/04—Endocrine or metabolic disorders
- G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/34—Genitourinary disorders
- G01N2800/347—Renal failures; Glomerular diseases; Tubulointerstitial diseases, e.g. nephritic syndrome, glomerulonephritis; Renovascular diseases, e.g. renal artery occlusion, nephropathy
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Physics & Mathematics (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
The invention provides an N-acetyl-beta-D-glucosaminidase detection kit with good stability, which belongs to the technical field of biological detection and comprises a reagent 1 and a reagent 2, wherein the reagent 1 comprises citric acid, sodium acetate, an ionic preparation, ascorbic acid oxidase and PC-300; the reagent 2 comprises TIRS, a stabilizer, potassium ferrocyanide, a surfactant, MPT-NAG, PC-300 and lipoprotein esterase. The 6-methyl-2-thiopyridine-N-acetyl-beta-D-glucoside is used as a substrate, and a proper reaction system, a buffer solution and a pH value are selected, so that the substrate is more stable, the anti-interference capability is better, and the sensitivity is higher. The invention also provides a preparation method and application of the N-acetyl-beta-D-glucosaminidase detection kit with good stability.
Description
Technical Field
The invention belongs to the technical field of biological detection, and relates to an N-acetyl-beta-D-glucosaminidase detection kit with good stability, a preparation method and an application background technology
N-acetyl-beta-D-glucosaminidase (NAG) is an acid hydrolase, also called urease, located in lysosomes and has a relative molecular weight of about 140000. It is widely distributed in human tissues, but is most abundant in prostate and renal proximal tubules. NAG has a molecular weight of about 130-140 KD, and NAG in serum cannot be excreted from urine by glomerular filtration under normal conditions. Elevation of NAG in urine is an early manifestation of kidney disease and is a sensitive indicator of tubular damage. In renal transplant patients, rejection can be detected early by urinary NAG measurement, and the NAG in the urine is increased 1-3 days before clinical indication. There is an increasing research on the use of late 80 s in the area of diabetic nephropathy, where it is noteworthy that the increase in urinary NAG may precede the increase in mALb in the early stages of diabetic nephropathy, suggesting that diabetic tubular damage may precede glomerular damage. A new idea has emerged to claim mALb and tubular marker proteins (NAG etc.) as routine indicators of early detection and monitoring of diabetic complications. In addition, the monitoring of NAG in urine has different degrees of elevation in various renal parenchymal diseases, is a sensitive indicator of kidney damage, and the elevation is seen in acute and chronic nephritis, renal failure caused by shock, nephrotic syndrome, toxic nephropathy and the like. Research shows that when the renal tubular injury is caused by diabetes, hypertensive glomerular early injury, drug nephrotoxicity, infection shock, renal transplantation rejection reaction and the like, the activity of NAG in urine is obviously increased and is earlier than other urinary enzymes, so the method has great value for early diagnosis of the renal tubular injury.
At present, NAG determination is the urine enzymology diagnostic item with the highest application rate, the reaction of the NAG determination to renal tubular injury is sensitive, and in addition, urine is used as a specimen, the NAG determination is a non-invasive inspection, is suitable for daily inspection and continuous dynamic analysis, and is also convenient for people to screen. The determination method of NAG in clinical application mainly comprises an radioimmunoassay, a fluorescence analysis method, an ultraviolet-visible spectrophotometry and the like, wherein the spectrophotometry takes the synthesis of a chromogen substrate as a main methodology. The substrate is decomposed by NAG, and the concentration of NAG is determined by measuring the absorbance of the decomposition product of the substrate at a specific wavelength. In the market, 5- [4- (3-methoxy-phenmethyl-rhodanine) ] -3-ammonium acetate-N-acetamido-beta-D-glucoside is generally adopted as a substrate, but a reagent prepared by using the substrate generally has the defects of poor stability, low analysis sensitivity and the like.
Disclosure of Invention
In order to solve the technical problems of poor stability and low sensitivity of the existing NAG detection reagent, the invention provides an N-acetyl-beta-D-glucosaminidase detection kit with good stability, which selects 6-methyl-2-thiopyridine-N-acetyl-beta-D-glucoside as a substrate and is matched with a proper reaction system, a buffer solution and a pH value, so that the substrate is more stable, the anti-interference capability is better and the sensitivity is higher.
The invention also provides a preparation method and application of the N-acetyl-beta-D-glucosaminidase detection kit with good stability.
The invention is realized by the following technical scheme:
an N-acetyl-beta-D-glucosaminidase detection kit with good stability comprises a reagent 1 and a reagent 2, wherein the reagent 1 comprises citric acid, sodium acetate, an ionic preparation, ascorbic acid oxidase and PC-300; the reagent 2 comprises TIRS, a stabilizer, potassium ferrocyanide, a surfactant, MPT-NAG, PC-300 and lipoprotein esterase.
Wherein, in the reagent 1, the concentrations of the components are as follows:
citric acid: 30-120moml/L, sodium acetate: 50-150 moll/L, ionic preparation: 0.5-20moml, ascorbic acid oxidase: 1-10KU/L, PC-300: 1-5ml/L, pH 4.80-5.20.
Further, in the reagent 2, the concentrations of the components are as follows:
and TIRS: 50-200 mol/L, stabilizer: 10-100g/L, potassium ferrocyanide: 0.05-1.5g/L, surfactant: 0.5-5g/L, MPT-NAG: 45-150moml/L, PC-300: 1-5ml/L, lipoprotein esterase: 1-10KU/L, pH 7.4-7.9.
Preferably, in the reagent 1, the concentrations of the components are as follows:
citric acid: 30moml/L, sodium acetate: 50 moll/L, ionic preparation: 1.0moml, ascorbic acid oxidase: 5KU/L, PC-300: 1ml/L, pH 4.80;
in the reagent 2, the concentrations of the components are as follows:
and TIRS: 50 moll/L, stabilizer: 10g/L, potassium ferrocyanide: 0.1g/L, surfactant: 1g/L, MPT-NAG: 50moml/L, PC-300: 1ml/L, lipoprotein esterase: 3KU/L, pH 7.4.
Further, the ionic agent comprises any one or more of sodium chloride, potassium sulfate, sodium sulfate, magnesium chloride and magnesium sulfate.
Further, the surfactant includes any one of Tritox-405, Emulgen A60, Triton-100 and GENAPOLX-080.
Further, the stabilizer includes any one of glycerin, ethylene glycol, PEG6000, PEG8000 and PEG 20000.
A preparation method of an N-acetyl-beta-D-glucosaminidase detection kit with good stability comprises the following steps:
preparing raw materials of citric acid, sodium acetate, an ionic preparation, ascorbic acid oxidase and PC-300 of a reagent 1 into a solution, and adjusting the pH value to 4.80-5.20 by adopting an acid liquid active alkali solution to obtain the reagent 1, wherein the concentration of each component of the obtained reagent 1 is as follows:
citric acid: 30-120moml/L, sodium acetate: 50-150 moll/L, ionic preparation: 0.5-20moml, ascorbic acid oxidase: 1-10KU/L, PC-300: 1-5 ml/L;
preparing a solution from the raw materials TIRS, a stabilizer, potassium ferrocyanide, a surfactant, MPT-NAG, PC-300 and lipoprotein esterase of the reagent 2, and adjusting the pH value to 7.4-7.9 by adopting an acid liquid and an active alkali liquid to obtain a reagent 2 with the concentration of each component:
and TIRS: 50-200 mol/L, stabilizer: 10-100g/L, potassium ferrocyanide: 0.05-1.5g/L, surfactant: 0.5-5g/L, MPT-NAG: 45-150moml/L, PC-300: 1-5ml/L, lipoprotein esterase: 1-10 KU/L.
Further, the acid solution is hydrochloric acid, and the alkali solution is a NaOH solution.
An application of an N-acetyl-beta-D-glucosaminidase detection kit with good stability in N-acetyl-beta-D-glucosaminidase detection.
One or more technical solutions in the embodiments of the present invention have at least the following technical effects or advantages:
the kit disclosed by the invention has the advantages that the anti-interference effect can be effectively realized by adding the ascorbic acid oxidase, the potassium ferrocyanide and the lipoprotein esterase, the stability of the reagent is enhanced by adding the stabilizer, the shelf life of the reagent is prolonged, the reaction of the reagent can be accelerated by adding the ionic agent and the surfactant, and the obtained kit can enable a substrate to be more stable, has better anti-interference capability and higher sensitivity.
Detailed Description
The present invention will be described in detail below with reference to specific embodiments and examples, and the advantages and various effects of the present invention will be more clearly apparent therefrom. It will be understood by those skilled in the art that these specific embodiments and examples are for the purpose of illustrating the invention and are not to be construed as limiting the invention.
Throughout the specification, unless otherwise specifically noted, terms used herein should be understood as having meanings as commonly used in the art. Accordingly, unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. If there is a conflict, the present specification will control.
Unless otherwise specifically stated, various raw materials, reagents, instruments, equipment and the like used in the present invention are commercially available or can be prepared by existing methods.
In order to solve the technical problems, the embodiment of the invention provides the following general ideas:
the invention adopts a 6-methyl-2-thiopyridine-N-acetyl-beta-D-glucosaccharase (MPT) substrate method to detect the activity of N-acetyl-beta-D-glucosaccharase in human serum or urine, and the reagent is stable for a long time, high in sensitivity and convenient to detect. However, the anti-interference capability of the existing MPT-NAG detection reagent is reduced after thermal damage, and the invention aims to solve the problem that the reagent can still keep good anti-interference capability after thermal damage.
Based on this, the substrate MPT-NAG is put into the reagent 2, and a proper reaction system, buffer solution and pH value are selected, so that the substrate is more stable, the anti-interference capability is better, and the sensitivity is higher.
Specifically, the N-acetyl-beta-D-glucosaminidase detection kit with good stability comprises a reagent 1 and a reagent 2, wherein the reagent 1 comprises citric acid, sodium acetate, an ionic preparation, ascorbic acid oxidase and PC-300; the reagent 2 comprises TIRS, a stabilizer, potassium ferrocyanide, a surfactant, MPT-NAG, PC-300 and lipoprotein esterase.
Wherein, in the reagent 1, the concentrations of the components are as follows:
citric acid: 30-120moml/L, sodium acetate: 50-150 moll/L, ionic preparation: 0.5-20moml, ascorbic acid oxidase: 1-10KU/L, PC-300: 1-5ml/L, pH 4.80-5.20.
Further, in the reagent 2, the concentrations of the components are as follows:
and TIRS: 50-200 mol/L, stabilizer: 10-100g/L, potassium ferrocyanide: 0.05-1.5g/L, surfactant: 0.5-5g/L, MPT-NAG: 45-150moml/L, PC-300: 1-5ml/L, lipoprotein esterase: 1-10KU/L, pH 7.4-7.9.
The ionic agent comprises any one or more of sodium chloride, potassium sulfate, sodium sulfate, magnesium chloride and magnesium sulfate. The surfactant comprises any one of Tritox-405, Emulgen A60, Triton-100 and GENAPOLX-080. The stabilizer comprises any one of glycerol, glycol, PEG6000, PEG8000 and PEG 20000.
The invention adopts an MPT-NAG detection method, N-acetyl-beta-D-glucosaminidase (NAG) in a sample catalyzes a substrate 6-methyl-2-thiopyridine-N-acetyl-beta-D-glucoside (MPT-NAG) to hydrolyze to generate 6-methyl-2-thiopyridine (MPT), and the absorbance rising rate of the MPT at a specific wavelength is in positive correlation with the NAG activity.
In the invention, the ascorbic acid oxidase must be added into the reagent 1, and when the reagent 1 is incubated with serum, the interference of vitamin C in the serum can be effectively cleared before the reagent 2 is added.
Potassium ferrocyanide must be added into the reagent 2, the potassium ferrocyanide cannot coexist with ASO enzyme, and the interference of bilirubin in serum on the measured value of the reagent can be effectively eliminated when the potassium ferrocyanide is added into the reagent 2.
The ionic preparation can effectively activate enzyme and substrate in the reagent and accelerate the reaction of the reagent.
Surfactant (b): tritox-405, Emulgen A60, Triton-100 and GENAPOLX-080 can act together with a stabilizer to completely dissolve substrates and accelerate reagent reaction.
The stabilizer (glycerol, glycol, PEG6000, PEG8000 and PEG20000) can act together with the surfactant to completely dissolve the substrate, accelerate the reaction of the reagent, stabilize the substrate in the reagent and prolong the shelf life of the reagent. The substrate 6-methyl-2-thiopyridine-N-acetyl-beta-D-glucoside needs to be placed in the reagent 2 to ensure that the reagent is more stable.
The interference of triglyceride can be eliminated by adding lipoprotein esterase into the reagent.
The kit can effectively resist interference by adding ascorbic acid oxidase, potassium ferrocyanide and lipoprotein esterase, enhances the stability of the reagent by adding a stabilizer, prolongs the quality guarantee period of the reagent, can accelerate the reaction of the reagent by adding an ionic preparation and a surfactant, and can ensure that a substrate is more stable, the anti-interference capability is better and the sensitivity is higher.
The following will explain in detail an N-acetyl- β -D-glucosaminidase detection kit with good stability in the present application with reference to examples, comparative examples and experimental data.
Examples
The present invention was provided with 6 comparative examples and 1 example.
Comparative example 1: the reagent is prepared by a traditional kit which takes 5- [4- (3-methoxy-phenmethyl-rhodanine) ] -3-ammonium acetate-N-acetamido-beta-D-glucoside as a substrate according to a comparison document CN 105203533B;
comparative example 2: the substrate MPT-NAG is placed in R1.
Comparative example 3: a lack of ethylene glycol;
comparative example 4: absence of Tritox-405;
comparative example 5: r2 has a ph of 8.5;
comparative example 6: r2 has a ph of 6.5.
1. The components of the comparative and example kits are shown in table 1:
TABLE 1 ingredient Table for comparative examples and example kits
2. Performance evaluation: the following tests were carried out for the above comparative examples and examples, respectively:
(1) precision: repeatedly measuring the same sample for 20 times, and calculating CV (%), wherein CV is less than or equal to 3.4% to meet the requirement;
(2) linear range: measuring samples in a range of 5-1000U/L, calculating a correlation coefficient, and calculating that r is less than or equal to 0.9900 to meet the requirement;
(3) accuracy: measuring the third-party quality control product, and calculating the deviation between the measured average value and the target value, wherein the deviation is less than or equal to 10 percent and meets the requirement;
(4) functional sensitivity: and (3) determining low-concentration samples with NAG concentration of 1U/L, 2.5U/L, 5U/L and 10U/L, determining each sample 10 times, calculating a mean value, a standard deviation, a deviation and a coefficient of variation, wherein CV is less than 10% and the deviation is less than 10% so as to meet the use requirement.
(5) Stability: the reagent was left at 37 ℃ for 7 days, and the above indices were evaluated: precision, linear range, accuracy, functional sensitivity;
(6) interference evaluation:
diluting the interfering substance with purified water according to a 1: 9 (the blank control serum is mixed serum of normal people, no interference substance is added, and the value is near the medical decision level) so that the final concentration after adding the serum meets the concentration to be evaluated, then the blank serum and the serum added with the interference substances with different concentrations are respectively measured by using a comparative example and an example group, each sample is measured for 3 times, the average value is calculated, and the deviation is calculated from the measured value of the blank control serum, namely the interference degree. And if the interference degree is less than 10%, judging to be anti-interference, otherwise, judging to be non-anti-interference.
The general interferents and concentrations in serum were: 1.0g/L ascorbic acid, 0.5g/L bilirubin and less than or equal to 10g/L triglyceride.
The test results are shown in tables 2 and 3:
TABLE 2 anti-interference data
Table 3 summary of performance evaluation data
TABLE 4 summary of sensitivity data
After 7 days of heat breaking of the reagent:
summary of sensitivity data before and after thermal disruption in examples 1 and 2 of the present invention
From the above experimental results, it is clear that the anti-interference ability of the reagents of each comparative example and example is almost the same before the heat-breaking, but after the heat-breaking, the anti-interference ability is not affected compared with that of comparative example 4 (after the heat-breaking of comparative example 4) and examples 1 and 2. The accuracy of the reagent after thermal disruption was poor due to poor stability before and after thermal disruption as compared with control 3, but the accuracy was poor as compared with control 4, and the analytical sensitivity was not as good as in examples 1 and 2 before and after thermal disruption. The anti-interference capability of the comparison group 5 and the comparison group 6 is reduced after thermal damage, and the linearity and the sensitivity are influenced after thermal damage.
Finally, it should also be noted that the terms "comprises," "comprising," or any other variation thereof, are intended to cover a non-exclusive inclusion, such that a process, method, article, or apparatus that comprises a list of elements does not include only those elements but may include other elements not expressly listed or inherent to such process, method, article, or apparatus.
While preferred embodiments of the present invention have been described, additional variations and modifications in those embodiments may occur to those skilled in the art once they learn of the basic inventive concepts. Therefore, it is intended that the appended claims be interpreted as including preferred embodiments and all such alterations and modifications as fall within the scope of the invention.
It will be apparent to those skilled in the art that various changes and modifications may be made in the present invention without departing from the spirit and scope of the invention. Thus, if such modifications and variations of the present invention fall within the scope of the claims of the present invention and their equivalents, the present invention is also intended to include such modifications and variations.
Claims (10)
1. The N-acetyl-beta-D-glucosaminidase detection kit with good stability is characterized by comprising a reagent 1 and a reagent 2, wherein the reagent 1 comprises citric acid, sodium acetate, an ionic preparation, ascorbic acid oxidase and PC-300; the reagent 2 comprises TIRS, a stabilizer, potassium ferrocyanide, a surfactant, MPT-NAG, PC-300 and lipoprotein esterase.
2. The N-acetyl-beta-D-glucosaminidase detection kit that has good stability according to claim 1, characterized in that, in the reagent 1, the concentration of each component is:
citric acid: 30-120moml/L, sodium acetate: 50-150 moll/L, ionic preparation: 0.5-20moml, ascorbic acid oxidase: 1-10KU/L, PC-300: 1-5ml/L, pH 4.80-5.20.
3. The kit for detecting N-acetyl-beta-D-glucosaminidase with good stability according to claim 1, characterized in that, in the reagent 2, the concentrations of the components are as follows:
and TIRS: 50-200 mol/L, stabilizer: 10-100g/L, potassium ferrocyanide: 0.05-1.5g/L, surfactant: 0.5-5g/L, MPT-NAG: 45-150moml/L, PC-300: 1-5ml/L, lipoprotein esterase: 1-10KU/L, pH 7.4-7.9.
4. The kit for detecting N-acetyl-beta-D-glucosaminidase with good stability of claim 1, characterized in that,
in the reagent 1, the concentrations of the components are as follows:
citric acid: 30moml/L, sodium acetate: 50 moll/L, ionic preparation: 1.0moml, ascorbic acid oxidase: 5KU/L, PC-300: 1ml/L, pH 4.80;
in the reagent 2, the concentrations of the components are as follows:
and TIRS: 50 moll/L, stabilizer: 10g/L, potassium ferrocyanide: 0.1g/L, surfactant: 1g/L, MPT-NAG: 50moml/L, PC-300: 1ml/L, lipoprotein esterase: 3KU/L, pH 7.4.
5. The N-acetyl-beta-D-glucosaminidase detection kit of claim 1 wherein the ionic agent comprises any one or more of sodium chloride, potassium sulfate, sodium sulfate, magnesium chloride and magnesium sulfate.
6. The kit for detecting N-acetyl-beta-D-glucosaminidase with good stability as claimed in claim 1, wherein the surfactant comprises any one of Tritox-405, Emulgen A60, Triton-100 and GENAPOLX-080.
7. The kit for detecting N-acetyl-beta-D-glucosaminidase with good stability as claimed in claim 1, wherein the stabilizer comprises any one of glycerol, ethylene glycol, PEG6000, PEG8000 and PEG 20000.
8. The method for preparing the N-acetyl-beta-D-glucosaminidase detection kit with good stability as defined in any one of claims 1-7, comprising:
preparing raw materials of citric acid, sodium acetate, an ionic preparation, ascorbic acid oxidase and PC-300 of the reagent 1 into a solution, and adjusting the pH value to 4.80-5.20 by using an acid liquid and an active alkali liquid to obtain the reagent 1 with the component concentration as claimed in claim 2;
preparing a solution from the raw materials TIRS, a stabilizer, potassium ferrocyanide, a surfactant, MPT-NAG, PC-300 and lipoprotein esterase of the reagent 2, and adjusting the pH value to 7.4-7.9 by using an acid liquid and an active alkali liquid to obtain the reagent 2 with the component concentration as defined in claim 3.
9. The method for preparing the N-acetyl-beta-D-glucosaminidase detection kit of claim 8, wherein the acid solution is hydrochloric acid and the alkali solution is NaOH solution.
10. Use of the kit of any one of claims 8 in an N-acetyl- β -D-glucosaminidase assay.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010771208.9A CN111826417B (en) | 2020-08-04 | 2020-08-04 | N-acetyl-beta-D-glucosaminidase detection kit with good stability, preparation method and application |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010771208.9A CN111826417B (en) | 2020-08-04 | 2020-08-04 | N-acetyl-beta-D-glucosaminidase detection kit with good stability, preparation method and application |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN111826417A true CN111826417A (en) | 2020-10-27 |
| CN111826417B CN111826417B (en) | 2023-01-17 |
Family
ID=72919350
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010771208.9A Active CN111826417B (en) | 2020-08-04 | 2020-08-04 | N-acetyl-beta-D-glucosaminidase detection kit with good stability, preparation method and application |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111826417B (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111778313A (en) * | 2020-08-13 | 2020-10-16 | 武汉生之源生物科技股份有限公司 | Angiotensin converting enzyme assay kit, preparation method and application |
| CN112501245A (en) * | 2020-11-09 | 2021-03-16 | 山东博科生物产业有限公司 | Novel N-acetyl-beta-D glucosaminidase detection reagent |
| CN112611727A (en) * | 2020-11-27 | 2021-04-06 | 江西乐成生物医疗有限公司 | Glutathione transferase detection kit, preparation method and application |
Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1687450A (en) * | 2005-04-18 | 2005-10-26 | 商纯尔 | Method measuring N-acetyl-beta-D-amidoglucosaccharase and liquid type stable reagent |
| CN102141568A (en) * | 2010-12-30 | 2011-08-03 | 北京九强生物技术股份有限公司 | Stable liquid single-reagent blood sugar kit |
| CN103134759A (en) * | 2011-11-26 | 2013-06-05 | 西安瑞捷生物科技有限公司 | Detection method for quantitative detection of 6-methyl-2-thiopyridine-N-acetyl-beta-D-glucosaminide |
| CN103134919A (en) * | 2011-11-26 | 2013-06-05 | 西安瑞捷生物科技有限公司 | Detection reagent for quantitative detection of 6-methyl-2-thiopyridine-N-acetyl-beta-D-glucosaminide |
| CN104946616A (en) * | 2015-05-12 | 2015-09-30 | 骏实生物科技(上海)有限公司 | General solid stabilizer used for in vitro diagnostic reagent and application method of general solid stabilizer |
| CN105603049A (en) * | 2016-01-18 | 2016-05-25 | 沈阳百创特生物科技有限公司 | Compound stabilizer and kit for in vitro diagnosis reagents |
| CN107991252A (en) * | 2017-11-23 | 2018-05-04 | 中山市创艺生化工程有限公司 | A kind of stabilizer for α-hydroxybutyrate dehydrogenase assay kit and preparation method thereof |
| CN108467882A (en) * | 2018-03-30 | 2018-08-31 | 潍坊市康华生物技术有限公司 | A kind of triglyceride detection kit |
| CN109856128A (en) * | 2018-12-24 | 2019-06-07 | 迪瑞医疗科技股份有限公司 | A kind of urine glucose detection test paper and preparation method thereof of ascorbic acid interference |
-
2020
- 2020-08-04 CN CN202010771208.9A patent/CN111826417B/en active Active
Patent Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1687450A (en) * | 2005-04-18 | 2005-10-26 | 商纯尔 | Method measuring N-acetyl-beta-D-amidoglucosaccharase and liquid type stable reagent |
| CN102141568A (en) * | 2010-12-30 | 2011-08-03 | 北京九强生物技术股份有限公司 | Stable liquid single-reagent blood sugar kit |
| CN103134759A (en) * | 2011-11-26 | 2013-06-05 | 西安瑞捷生物科技有限公司 | Detection method for quantitative detection of 6-methyl-2-thiopyridine-N-acetyl-beta-D-glucosaminide |
| CN103134919A (en) * | 2011-11-26 | 2013-06-05 | 西安瑞捷生物科技有限公司 | Detection reagent for quantitative detection of 6-methyl-2-thiopyridine-N-acetyl-beta-D-glucosaminide |
| CN104946616A (en) * | 2015-05-12 | 2015-09-30 | 骏实生物科技(上海)有限公司 | General solid stabilizer used for in vitro diagnostic reagent and application method of general solid stabilizer |
| CN105603049A (en) * | 2016-01-18 | 2016-05-25 | 沈阳百创特生物科技有限公司 | Compound stabilizer and kit for in vitro diagnosis reagents |
| CN107991252A (en) * | 2017-11-23 | 2018-05-04 | 中山市创艺生化工程有限公司 | A kind of stabilizer for α-hydroxybutyrate dehydrogenase assay kit and preparation method thereof |
| CN108467882A (en) * | 2018-03-30 | 2018-08-31 | 潍坊市康华生物技术有限公司 | A kind of triglyceride detection kit |
| CN109856128A (en) * | 2018-12-24 | 2019-06-07 | 迪瑞医疗科技股份有限公司 | A kind of urine glucose detection test paper and preparation method thereof of ascorbic acid interference |
Non-Patent Citations (1)
| Title |
|---|
| 余长福: "MPT-NAG测定N-乙酰-β-D-氨基葡萄糖苷酶的应用价值", 《检验医学与临床》 * |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111778313A (en) * | 2020-08-13 | 2020-10-16 | 武汉生之源生物科技股份有限公司 | Angiotensin converting enzyme assay kit, preparation method and application |
| CN111778313B (en) * | 2020-08-13 | 2022-11-18 | 武汉生之源生物科技股份有限公司 | Angiotensin converting enzyme assay kit, preparation method and application |
| CN112501245A (en) * | 2020-11-09 | 2021-03-16 | 山东博科生物产业有限公司 | Novel N-acetyl-beta-D glucosaminidase detection reagent |
| WO2022095576A1 (en) * | 2020-11-09 | 2022-05-12 | 山东博科生物产业有限公司 | NOVEL N-ACETYL-β-D GLUCOSAMINIDASE DETECTION AGENT |
| CN112611727A (en) * | 2020-11-27 | 2021-04-06 | 江西乐成生物医疗有限公司 | Glutathione transferase detection kit, preparation method and application |
Also Published As
| Publication number | Publication date |
|---|---|
| CN111826417B (en) | 2023-01-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN111826417B (en) | N-acetyl-beta-D-glucosaminidase detection kit with good stability, preparation method and application | |
| US4729959A (en) | Glucose reference control for glucose test strips | |
| WO2022095576A1 (en) | NOVEL N-ACETYL-β-D GLUCOSAMINIDASE DETECTION AGENT | |
| CN105334211B (en) | It is a kind of while detect the kit of sodium and creatinine in urine | |
| CN111394424B (en) | Human serum creatinine content detection reagent and method for resisting calcium dobesilate interference | |
| CN106367472A (en) | Kit and method for determining uric acid | |
| CN109212176B (en) | A kind of pyruvic acid assay kit and its preparation method and application | |
| CN111808921A (en) | Trinder reaction-based detection kit and application thereof | |
| CN112029817B (en) | Creatinine detection kit and application method thereof | |
| CN108535244A (en) | Creatinine content detection reagent in a kind of human serum of anti-Calcium Dobesilate interfering effects of drug | |
| CN111304283A (en) | Kit for determining HCY based on cyclic enzyme rate method and preparation and use methods thereof | |
| CN105424934A (en) | N-acetyl-beta-D glucosidase reagent and detection method | |
| CN112710853B (en) | Anti-interference and stable serum direct bilirubin (enzyme method) determination kit and preparation method and application thereof | |
| CN105203533B (en) | A kind of high N acetyl β D UNAG detection reagents of sensitivity for analysis | |
| CN103773833A (en) | Creatinine measurement reagent | |
| CN111965365B (en) | Fructosamine assay kit | |
| CN111778313B (en) | Angiotensin converting enzyme assay kit, preparation method and application | |
| CN112710854A (en) | Anti-interference and stable serum total bilirubin (enzyme method) determination kit and preparation method and application thereof | |
| Lopes et al. | Glucose concentration in dairy cows measured using 6 handheld meters designed for human use | |
| CN103397076B (en) | The application in the biochemical reagents of negative value or null value is there is in chlorate in preparation elimination measurement result | |
| CN108007922B (en) | A kind of kit detecting glucose using luminol chemiluminescence analysis | |
| CN111893163B (en) | High-density lipoprotein 3 cholesterol detection kit, preparation method and application | |
| CN107254508B (en) | H2O2Kit for detecting sialic acid by coupled indicator system | |
| CN110343740A (en) | A kind of highly sensitive Plasma lactate method and lactate acid detection kit | |
| CN113514451B (en) | Blood creatinine detection reagent ball and blood creatinine detection chip |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |